
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech.
View full story: https://www.biocentury.com/article/660408
#Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation
00:00 - Introduction
03:24 - Biotech Under Threat
10:38 - CEO Compensation
15:39 - Competing with China
22:08 - U.S. Policy Prescriptions
30:00 - Looking Ahead
View full story: https://www.biocentury.com/article/660408
#Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation
00:00 - Introduction
03:24 - Biotech Under Threat
10:38 - CEO Compensation
15:39 - Competing with China
22:08 - U.S. Policy Prescriptions
30:00 - Looking Ahead
Loading content...
Read the full transcript
Matterfact has every podcast on Apple Podcasts and Spotify: 700K+ channels, 120M+ episodes.
The candid version is on a podcast,
not the earnings call.
Matterfact turns the conversations your coverage is already having into a searchable, citable record — across every episode, not just this one.